BTL Aesthetics has announced a major milestone: over one million EMFACE® treatments have now been performed globally. This reflects the increasing demand for non-invasive facial rejuvenation solutions.
EMFACE® is the first and only device to simultaneously deliver High-Intensity Facial Electrical Stimulation (HIFES™) and Synchronized Radiofrequency (RF). It is intended for local muscle stimulation, tissue heating, increased circulation, muscle strengthening, and supporting wrinkle and rhytid reduction.
With a duration of 20 minutes, each treatment includes radiofrequency, which gently heats the skin to support collagen and tissue quality, while HIFES™ technology stimulates underlying muscles to enhance tone and reduce facial wrinkles.
A recent innovation, the EMFACE® Eye Applicators, target the delicate periorbital region—supporting circulation and muscle function in one of the most expressive areas of the face.
Key features of EMFACE include:
- Dual-modality treatment: combines RF and muscle stimulation in one session
- Clinically supported: over 17 peer-reviewed studies
- Non-invasive with minimal downtime
EMFACE® is often incorporated into tailored treatment programs.
To learn more visit btlaesthetics.com.au/for-providers/emface-providers
About BTL Aesthetics
Founded in 1993, BTL is a global leader in non-invasive aesthetic technologies, offering evidence-based solutions including EMSCULPT NEO®, EXION™, EMSELLA®, and EXILIS ULTRA 360®.
